financetom
Business
financetom
/
Business
/
Capstone Infrastructureand Sawridge First Nation Start Commercial Operations at Buffalo Atlee Wind Farms
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Capstone Infrastructureand Sawridge First Nation Start Commercial Operations at Buffalo Atlee Wind Farms
Jul 9, 2024 2:20 PM

05:14 PM EDT, 07/09/2024 (MT Newswires) -- Capstone Infrastructure (CSE-PA.TO) and Sawridge First Nation on Tuesday announced the successful commissioning of four wind farms in Alberta.

According to a statement, the Buffalo Atlee 1, 2, 3, and 4 Wind Farms add another 61 MW of emissions-free electricity capacity to the Alberta grid, which is expected to provide enough power for approximately 26,000 homes in Alberta homes every year. Together, the four facilities are expected to avoid fossil fuel carbon emissions of approximately 93,000 metric tonnes annually at the start of commercial operation, Tuesday's statement said.

"Capstone prides itself on forging partnerships that support the energy transition while delivering economic benefits for local communities and our Indigenous partners, and all of the Buffalo Atlee project partners shares this same vision," said chief executive David Eva said in a release.

Tuesday's statement noted the electricity produced at the Buffalo Atlee 2 and 4 Wind Farms will be purchased by Gibson Energy ( GBNXF ) , under the terms of the 15-year renewable-power purchase agreement signed by Capstone, Sawridge, and Gibson in 2023. Gibson said the PPA demonstrates a commitment to the low-carbon transition and achieving its emission reduction targets, including a goal of Net Zero by 2050.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cognyte Software Swings to Fiscal Q3 Non-GAAP Net Income as Revenue Rises; Fiscal 2025 Outlook Boosted
Cognyte Software Swings to Fiscal Q3 Non-GAAP Net Income as Revenue Rises; Fiscal 2025 Outlook Boosted
Dec 11, 2024
07:49 AM EST, 12/11/2024 (MT Newswires) -- Cognyte Software ( CGNT ) reported fiscal Q3 non-GAAP earnings Wednesday of $0.02 per diluted share, swinging from a loss of $0.01 a year earlier. Two analysts polled by FactSet expected earnings of $0.11. Revenue for the quarter ended Oct. 31 was $89 million, up from $79.4 million a year earlier. Two analysts...
Top Premarket Decliners
Top Premarket Decliners
Dec 11, 2024
07:49 AM EST, 12/11/2024 (MT Newswires) -- Q32 Bio ( QTTB ) shares slumped 65% pre-bell Wednesday after the company said late Tuesday its phase 2a trial of a treatment candidate for atopic dermatitis failed to meet its primary endpoint. ImmunityBio ( IBRX ) dropped 27% after the company priced a $100 million stock offering. Comstock (CHCI) shares were down...
Candel Therapeutics Says Prostate Cancer Drug Trial Meets Primary Endpoint; Shares Jump
Candel Therapeutics Says Prostate Cancer Drug Trial Meets Primary Endpoint; Shares Jump
Dec 11, 2024
07:48 AM EST, 12/11/2024 (MT Newswires) -- Candel Therapeutics ( CADL ) shares climbed by more than 120% in premarket trading after the biopharmaceutical company said a phase 3 trial of CAN-2409 to treat localized prostate cancer met its primary endpoint. The primary endpoint was to demonstrate a statistically significant improvement in disease-free survival compared to the control arm. The...
Monte Rosa Therapeutics Preclinical Trial of Potential Breast Cancer Therapy Shows Less Toxicity, Tumor Regression
Monte Rosa Therapeutics Preclinical Trial of Potential Breast Cancer Therapy Shows Less Toxicity, Tumor Regression
Dec 11, 2024
07:48 AM EST, 12/11/2024 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) said Wednesday that data from a preclinical trial of its drug MRT-9643 as a potential treatment for HR-positive/HER2-negative breast cancer has superior selectivity relative to other clinical-stage cyclin-dependent kinase 2 inhibitors and induced robust downstream CDK2 pathway suppression. MRT-9643 drove deep tumor regression in preclinical cellular models...
Copyright 2023-2026 - www.financetom.com All Rights Reserved